Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.43 |
| ▸ | FSHR | P23945 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861471 | 0.87 | MGLL (0.49) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL6529297 | 0.83 | TSHR (0.45) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL6528111 | 0.81 | MGLL (0.49) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL6530879 | 0.77 | MGLL (0.45) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL6530872 | 0.77 | MGLL (0.45) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL8133353 | 0.76 | NPC1 (0.58) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL7839750 | 0.70 | MGLL (0.54) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL16374601 | 0.70 | MGLL (0.51) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL3831190 | 0.69 | SMN1; SMN2 (0.55) | MGLLTSHRTP53MAPTSMN1; SMN2 | |
| SCHEMBL6532124 | 0.69 | NPC1 (0.60) | MGLLTSHRTP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | claimed |
| US-7012088-B2 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1599470-A1 | ANTIBACTERIAL INDOLONE OXAZOLIDINONES, INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia & Upjohn Company LLC (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004074282-A1 | ANTIBACTERIAL INDOLONE OXAZOLIDINONES, INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | OXA1L, IDO1, NDUFS7 | MGLL 2261/4885TSHR 3233/4885TP53 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.